PATH vs ROIV · P/E 19, rev $1.61B vs rev $29.1M
Uipath Inc (PATH) versus Roivant Sciences Ltd (ROIV) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported ROIV revenue for 2025-03-31 was $29.1M. Net income was -$356.7M. Revenue was down 11.2% from 2024-03-31 to 2025-03-31. ROIV currently screens at market cap $7.47B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. ROIV currently screens at market cap $7.47B.
Not investment advice. Open the PATH and ROIV stock pages for the full models.
Not investment advice.